The role of microbiota in nonalcoholic fatty liver disease

被引:37
作者
Di Ciaula, Agostino [1 ]
Bonfrate, Leonilde [1 ]
Portincasa, Piero [1 ]
机构
[1] Univ Bari, Clin Med A Murri, Dept Biomed Sci & Human Oncol, Med Sch, Bari, Italy
关键词
fatty liver; gut-liver axis; intestine; liver steatosis; metabolic syndrome; Metabolome; microbiota; GUT MICROBIOTA; BILE-ACID; NATURAL-HISTORY; UNITED-STATES; HEPATOCELLULAR-CARCINOMA; INTESTINAL PERMEABILITY; HEPATIC STEATOSIS; DOUBLE-BLIND; RISK-FACTORS; OBESE MICE;
D O I
10.1111/eci.13768
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nonalcoholic fatty liver disease (NAFLD) is the most frequent liver disease worldwide. Gut microbiota can play a role in the pathogenesis of NAFLD since dysbiosis is associated with reduced bacterial diversity, altered Firmicutes/Bacteroidetes ratio, a relative abundance of alcohol-producing bacteria, or other specific genera. Changes can promote disrupted intestinal barrier and hyperpermeability, filtration of bacterial products, activation of the immune system, and pro-inflammatory changes in the intestine, in the liver, and at a systemic level. Microbiota-derived molecules can contribute to the steatogenic effects. The link between gut dysbiosis and NAFLD, however, is confused by several factors which include age, BMI, comorbidities, dietary components, and lifestyle. The role of toxic chemicals in food and water requires further studies in both gut dysbiosis and NAFLD. We can anticipate that gut microbiota manipulation will represent a potential therapeutic tool to delay or reverse the progression of NAFLD, paving the way to primary prevention measures.
引用
收藏
页数:24
相关论文
共 213 条
[1]   A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease [J].
Abul-Husn, N. S. ;
Cheng, X. ;
Li, A. H. ;
Xin, Y. ;
Schurmann, C. ;
Stevis, P. ;
Liu, Y. ;
Kozlitina, J. ;
Stender, S. ;
Wood, G. C. ;
Stepanchick, A. N. ;
Still, M. D. ;
McCarthy, S. ;
O'Dushlaine, C. ;
Packer, J. S. ;
Balasubramanian, S. ;
Gosalia, N. ;
Esopi, D. ;
Kim, S. Y. ;
Mukherjee, S. ;
Lopez, A. E. ;
Fuller, E. D. ;
Penn, J. ;
Chu, X. ;
Luo, J. Z. ;
Mirshahi, U. L. ;
Carey, D. J. ;
Still, C. D. ;
Feldman, M. D. ;
Small, A. ;
Damrauer, S. M. ;
Rader, D. J. ;
Zambrowicz, B. ;
Olson, W. ;
Murphy, A. J. ;
Borecki, I. B. ;
Shuldiner, A. R. ;
Reid, J. G. ;
Overton, J. D. ;
Yancopoulos, G. D. ;
Hobbs, H. H. ;
Cohen, J. C. ;
Gottesman, O. ;
Teslovich, T. M. ;
Baras, A. ;
Mirshahi, T. ;
Gromada, J. ;
Dewey, F. E. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (12) :1096-1106
[2]   The natural history of nonalcoholic fatty liver disease: A population-based cohort study [J].
Adams, LA ;
Lymp, JF ;
St Sauver, J ;
Sanderson, SO ;
Lindor, KD ;
Feldstein, A ;
Angulo, P .
GASTROENTEROLOGY, 2005, 129 (01) :113-121
[3]   Bile acids associate with specific gut microbiota, low-level alcohol consumption and liver fibrosis in patients with non-alcoholic fatty liver disease [J].
Adams, Leon A. ;
Wang, Zhengyi ;
Liddle, Chris ;
Melton, Phillip E. ;
Ariff, Amir ;
Chandraratna, Harsha ;
Tan, Jeremy ;
Ching, Helena ;
Coulter, Sally ;
de Boer, Bastiaan ;
Christophersen, Claus T. ;
O'Sullivan, Therese A. ;
Morrison, Mark ;
Jeffrey, Gary P. .
LIVER INTERNATIONAL, 2020, 40 (06) :1356-1365
[4]   Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults [J].
Alexander, Myriam ;
Loomis, A. Katrina ;
van der Lei, Johan ;
Duarte-Salles, Talita ;
Prieto-Alhambra, Daniel ;
Ansell, David ;
Pasqua, Alessandro ;
Lapi, Francesco ;
Rijnbeek, Peter ;
Mosseveld, Mees ;
Avillach, Paul ;
Egger, Peter ;
Dhalwani, Nafeesa N. ;
Kendrick, Stuart ;
Celis-Morales, Carlos ;
Waterworth, Dawn M. ;
Alazawi, William ;
Sattar, Naveed .
BMJ-BRITISH MEDICAL JOURNAL, 2019, 367
[5]   Randomised clinical trial: the beneficial effects of VSL# 3 in obese children with non-alcoholic steatohepatitis [J].
Alisi, A. ;
Bedogni, G. ;
Baviera, G. ;
Giorgio, V. ;
Porro, E. ;
Paris, C. ;
Giammaria, P. ;
Reali, L. ;
Anania, F. ;
Nobili, V. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 39 (11) :1276-1285
[6]  
Aller R, 2011, EUR REV MED PHARMACO, V15, P1090
[7]   Dietary protein insufficiency: an important consideration in fatty liver disease? [J].
Ampong, Isaac ;
Watkins, Adam ;
Gutierrez-Merino, Jorge ;
Ikwuobe, John ;
Griffiths, Helen R. .
BRITISH JOURNAL OF NUTRITION, 2020, 123 (06) :601-609
[8]  
Angulo P, 2007, NUTR REV, V65, pS57, DOI [10.1111/j.1753-4887.2007.tb00329.x, 10.1301/nr.2007.jun.S57-S63]
[9]   Dietary Iron Supplementation Alters Hepatic Inflammation in a Rat Model of Nonalcoholic Steatohepatitis [J].
Atarashi, Machi ;
Izawa, Takeshi ;
Miyagi, Rena ;
Ohji, Shoko ;
Hashimoto, Ai ;
Kuwamura, Mitsuru ;
Yamate, Jyoji .
NUTRIENTS, 2018, 10 (02)
[10]   Sex-Dependent Effects of Cadmium Exposure in Early Life on Gut Microbiota and Fat Accumulation in Mice [J].
Ba, Qian ;
Li, Mian ;
Chen, Peizhan ;
Huang, Chao ;
Duan, Xiaohua ;
Lu, Lijun ;
Li, Jingquan ;
Chu, Ruiai ;
Xie, Dong ;
Song, Haiyun ;
Wu, Yongning ;
Ying, Hao ;
Jia, Xudong ;
Wang, Hui .
ENVIRONMENTAL HEALTH PERSPECTIVES, 2017, 125 (03) :437-446